| CASE REPORT |
|
| Year : 2021 | Volume
: 20
| Issue : 3 | Page : 316-318 |
|
|
Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
Magdalena Mileva, Zéna Wimana, Patrick Flamen, Ioannis Karfis
Department of Nuclear Medicine, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
Correspondence Address:
Dr. Magdalena Mileva
Department of Nuclear Medicine, Jules Bordet Institute - Université Libre de Bruxelles, Rue Héger-Bordet 1, B-1000, Barussels
Belgium
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/wjnm.WJNM_120_20
|
|
|
We present a case of Grade II, well-differentiated rectal neuroendocrine tumor in a 39-year-old patient. Following different sequential treatment modalities, the disease progressed both on metabolic (18F-fluorodeoxyglucose positron emission tomography-computed tomography [18F-FDG PET/CT]) and somatostatin receptor (SSTR)-imaging (68Ga-DOTA-Tyr3-octreotate [68Ga-DOTATATE] PET/CT), and the patient received three cycles of peptide receptor radiotherapy (PRRT). Two years later, upon new progression due to the appearance of metabolically active, 68Ga-DOTATATE PET/CT-negative liver lesions, targeted treatment with everolimus was introduced. Further morphologic and metabolic progression occurred 4 months after everolimus initiation, however, this time liver lesions demonstrated increased SSTR-expression on68Ga-DOTATATE PET/CT. Thus, the patient became eligible for a second PRRT course. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Users Online: 75 
